INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Public ClinicalTrials.gov record NCT05359692. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 2, Open-Label, Multicenter Study of INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Study identification
- NCT ID
- NCT05359692
- Recruitment status
- Withdrawn
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Incyte Biosciences International Sàrl
- Industry
- Enrollment
- Not listed
Conditions and interventions
Conditions
Interventions
- INCAGN01876 Biological
- retifanlimab Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years to 99 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 28, 2023
- Primary completion
- Apr 19, 2024
- Completion
- Jan 10, 2025
- Last update posted
- Sep 14, 2023
2023 – 2025
United States locations
- U.S. sites
- 17
- U.S. states
- 15
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Uab Medicine-the Kirklin Clinic | Birmingham | Alabama | 35233 | — |
| University of California San Diego Medical Center, Moores Cancer Center | La Jolla | California | 92093 | — |
| Stanford University | Palo Alto | California | 94304 | — |
| Toi Clinical Research | Whittier | California | 90603 | — |
| University of Chicago | Chicago | Illinois | 60637 | — |
| University of Kansas Cancer Center | Westwood | Kansas | 66205 | — |
| Norton Cancer Institute | Louisville | Kentucky | 40202 | — |
| University of Maryland-Greenebaum Cancer Center | Baltimore | Maryland | 21201 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| John Theurer Cancer Center, Hackensack University Medical Center | Hackensack | New Jersey | 07601 | — |
| Mount Sinai Prime | New York | New York | 10029 | — |
| University of Cincinnati Cancer Institute | Cincinnati | Ohio | 45219 | — |
| Providence Portland Med. Ctr | Portland | Oregon | 97213 | — |
| Md Anderson Cancer Center | Houston | Texas | 77030 | — |
| University of Utah | Salt Lake City | Utah | 84112 | — |
| The Adult Outpatient Pavilion At Vcu | Richmond | Virginia | 23219 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05359692, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 14, 2023 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05359692 live on ClinicalTrials.gov.